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Abstract
Allergies mediated by immunoglobulin E (IgE) are the most common immunological 
hypersensitivity diseases. The prevalence has been continuously increasing in recent 
decades, and more than 25% of the population is currently affected. Symptoms of aller‐
gies can be observed in the skin and respiratory and gastrointestinal tracts, and systemic 
manifestations include anaphylactic shock. If an allergy is not properly diagnosed and 
treated, it tends to progress to a severe and chronic debilitating disease. Understanding 
the mechanisms by which the immune system induces and controls allergic inflamma‐
tion depends on knowing the structure of several allergens and identifying epitopes, 
which are critical for the design of new strategies for treating allergies. Strategies for 
immunotherapy will be reviewed. Allergen‐specific immunotherapy has been used for 
nearly a century and remains one of the few antigen‐specific treatments for inflammatory 
diseases. There is a strong rationale for improving the efficacy of allergen‐specific immu‐
notherapy by reducing the incidence and severity of adverse reactions mediated by IgE. 
Approaches to address this problem, including the use of modified allergens, synthetic 
peptides as vaccines, and alternative strategies for blocking IgE, will be discussed.
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1. Allergic mechanism
An allergen is defined as a normally harmless substance, found in the environment or food, 
which can produce asthma, fever, eczema, or gastrointestinal discomfort upon contact with 
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a previously sensitized person. An allergy is commonly defined as an immediate or type I 
hypersensitivity reaction where symptoms appear rapidly and are caused by exposure to 
exogenous macromolecules known as antigens or allergens. The hypersensitivity reaction has 
two phases: sensitization, when the subject is first exposed to the antigen, and the subsequent 
reaction, when the subject is again exposed to the antigen [1]. The first sensitization of a body 
begins with the first contact with an antigen, which induces an allergy. The allergen pene‐
trates the airways of the body or other tissues and is found by antigen‐presenting cells (APCs) 
such as macrophages and/or dendritic cells, which encyst and proteolytically cleave the for‐
eign substance. The peptide fragments generated, known as T cell epitopes, are directed to 
the outer membrane of the APC by the major histocompatibility class II (MHC II) complex in 
the form of a complex peptide‐MHC class II [2]. The T‐helper lymphocytes (Th1 and/or Th2) 
recognize these exposed epitopes and together with B cells initiate the immune response. 
The activation clones specific for the antigen, Th2 cells, are essential for the development of 
atopic diseases, because these cells activated by contact with APCs produce cytokines and 
interleukins 4 (IL‐4) and 5 (IL‐5). These interleukins act as signals, among other functions, 
for the biosynthesis of immunoglobulin E (IgE) by B lymphocytes. An immunoglobulin, IgE, 
binds to the surface of mast cells and basophils by FcЄRI receptors. A subsequent exposure 
to the same antigen, the second sensitization, leads to a substantial allergic response. The 
antigen‐specific segments (IgE epitopes) are cross‐linked to the IgE bound to the mast and/or 
basophil cells after interaction with the allergen, activating intracellular messengers, and the 
subsequent release of cellular mediators such as histamine and prostaglandins, which in turn 
induce physiological and anatomical changes that trigger the allergic symptoms of immedi‐
ate hypersensitivity [3, 4].
IgE antibodies generated in response to a specific allergen interact with this allergen and 
trigger a series of intracellular reactions leading to the release of histamine and other inflam‐
matory mediators. Histamine plays a key role in the allergic response. The release of hista‐
mine causes the smooth muscles of the gastrointestinal and respiratory tracts to contract, 
stimulates nerves, and dilates blood vessels [5, 6]. These effects of histamine include, among 
other clinical manifestations, erythema, flushing, nasal congestion, pruritus, headache, hypo‐
tension, tachycardia, and bronchoconstriction [5]. There are four main subtypes of histamine 
receptors: H1, H2, H3, and H4. These receptors are G‐protein‐coupled receptors that transfer 
extracellular signals via G proteins, acting as intermediates between cell‐surface receptors 
and second intracellular messengers [6, 7]. The H1 receptor is the main mediator subtype of 
the allergic response causing allergic symptoms. In addition to its role in the immediate aller‐
gic response, histamine contributes to the late allergic response by stimulating the production 
of cell‐adhesion molecules, class II antigens, and cytokines [6].
2. Tolerance induction
Immune tolerance can develop against any substance, and multiple mechanisms are involved. 
The lack of response of immune tolerance can lead to the development of various diseases 
such as:
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• allergies
• asthma
• tumors
• chronic infections
• transplant organ rejection
• graft versus host disease
• many autoimmune diseases [8].
The generation of regulatory T (Treg) cells initiates tolerance. Peripheral tolerance is initi‐
ated by the secretion of IL‐10 and TGF‐β by allergen‐specific Treg cells during continu‐
ous exposure. The induction of allergen‐specific tolerance is associated with an increase in 
FOXP3+CD25+CD3+ cells in the nasal mucosa [9]. Atopic individuals have a reduced capacity 
to proliferate CD25+ and CD4 Treg cells, which indicates the mechanisms of failure of toler‐
ance allergens. A clonal shift occurs during tolerance fromTh1, Th2 to Th1 (Table 1). B cells 
are stimulated by the action of IL‐10 to produce IgG (particularly IgG4) and to suppress IgE 
production, which prevents the development of allergic symptoms in the tolerogenic indi‐
vidual [9–11] (Table 2).
If an allergy is not properly diagnosed and treated, it tends to progress to a severe and chronic 
debilitating disease.
Many treatments have been developed to circumvent the symptoms of allergic diseases, most 
of which use histamine inhibitors that mask the symptoms of the allergy. Allergen‐specific 
immunotherapy (ASIT), however, is the only long‐term preventive and long‐term treatment 
for allergic diseases. ASIT involves the administration of a specific allergen, so it induces a 
specific immunological tolerance to the allergen. ASIT has been used for more than 100 years, 
but the mechanism of action has only recently been resolved [12].
IL‐10 Inhibits the production of proinflammatory cytokines 
and the activation of Th2 and Th1
TGF‐β Inhibits the proliferation and differentiation of B and T 
lymphocytes
IgG4 Blocking antibody that inhibits the activation of effector 
cells by affecting the binding of allergen to IgE at Fcϵ 
receptors on the membranes of mast cells and basophils
HR2 Negatively regulates Th1‐ and Th2‐type responses; these 
are G‐protein‐associated histamine receptors, which 
regulate various immunological events due to cAMP 
formation. Histamine induces the production of IL‐10 by 
DC and Th2 and enhances the secretory activity of TGF 
in T cells
Table 1. Molecules with effector functions in allergen tolerance.
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In this chapter, we will describe the most common allergy treatments using antihistamines 
and emphasize the new methodologies of allergen‐specific immunotherapy (ASIT) as a pro‐
phylactic treatment and IgE blockade as a therapeutic treatment.
3. Approaches for allergy treatment
3.1. Antihistaminic treatment
Researchers have devoted their efforts for many years to the development of effective and 
safe strategies for the treatment of allergy to alleviate the symptoms triggered by the body’s 
responses to allergens [1, 13, 14]. Antihistamines are currently the most commonly used treat‐
ment. These drugs are used to alleviate allergic symptoms, that is, they are based on the con‐
sequences of the allergy [5]. First‐generation antihistamines, or H1‐receptor antagonists, may 
have undesirable side effects on the central nervous system, even at therapeutic doses, due to 
their ability to cross the blood‐brain barrier rather than to their lack of selectivity. Side effects 
include sleepiness, sedation, and fatigue that may lead to reduced cognitive, memory, and psy‐
chomotor performance [7, 15]. First‐generation antihistamines include doxepin, diphenhydr‐
amine, pyrilamine, chlorpheniramine, hydroxyzine, promethazine, and cyproheptadine [6].
A new class of antihistamine has been developed. Second‐generation H1 antagonists cannot 
cross the blood‐brain barrier as easily and have a greater affinity to H1 receptors, decreasing 
their sedative effects compared to the first‐generation drugs [7]. These antihistaminic agents 
include cetirizine, ebastine, epinastine, fexofenadine, loratadine, desloratadine, levocetiri‐
zine, and rupatadine. The second‐generation antihistamines cause fewer adverse effects, but 
some drugs, for example, levocetirizine, may cause drowsiness, and fexofenadine has a brief 
effect and may require more than one daily dose. Treatment with antihistaminic drugs does 
not address the cause of allergic responses but only alleviates their symptoms [7, 14, 16].
3.2. Allergen‐specific immunotherapy (ASIT)
Immunotherapy was first conceived in 1911, from which a type of therapy was developed 
that used allergens as a tool for the development of immunological tolerance in sensitized 
individuals [17]. The term “desensitization” was replaced with “hypo‐sensitization.” The 
term “immunotherapy” became popular only in the 1980s and “specific immunotherapy” is a 
Treg Secretors of TGF‐β and IL‐10; induce Foxp3 expression, 
Th2 suppression; direct, and indirect suppression of 
mast cells, basophils, and eosinophils; stimulate B 
lymphocytes in IgG4 production and IgE suppression
Breg Expression of IL‐10 and IgG4
Eosinophils Decrease the activity of inflammatory mediator secretion 
(histamine and leukotrienes) by the action of IL‐10 and 
TGF secreted by regulatory cellsBasophils
Mast cells
Table 2. Roles of cells in allergen tolerance.
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commonly used term. When immunotherapy involves the direct use of allergens as immuno‐
therapeutics, the appropriate term is ASIT [12]. ASIT has been used for more than a century 
and remains one of the few antigen‐specific treatments for inflammatory diseases.
ASIT consists of the gradual administration of doses of a specific allergen or part of that aller‐
gen to reduce the sensitivity and consequently to decrease the symptomatic reactions to a 
future exposure of the allergic individual to the causative natural agent [1, 18]. ASIT is a widely 
used therapeutic strategy for treating allergic rhinitis, venom‐induced hypersensitivity, some 
drug allergies, and mild bronchial asthma [13]. The mechanisms of ASIT are not yet clear but 
include modulating both T and B cell responses, thereby reducing the incidence and severity 
of IgE‐mediated adverse reactions [19]. Some of the immunological changes that occur dur‐
ing ASIT have been elucidated [1]. ASIT increases the level of allergen‐specific IgA and IgG4 
antibodies and decreases the level of allergen‐specific IgE antibodies. Oral, sublingual, and 
subcutaneous immunotherapies are used the most in the treatment of hypo‐sensitization in 
various types of allergies. These three mechanisms of immunotherapies, however, are specific 
to particular allergens, so the therapy is effective only for the particular allergen.
Approaches to improving ASIT include the use of modified recombinant allergens, novel 
adjuvants, and alternative routes of administration. Recombinant allergens are similar to 
wild‐type allergens, generally equivalent in structure and properties, but with alterations in 
their epitopes that do not guarantee their ability to trigger an allergic response [20].
3.2.1. Recombinant hypoallergenic peptides for immunotherapy
Valenta et al. using purified recombinant allergens and derivatives of recombinant hypoal‐
lergenic allergens has identified the induction of the production of IgG‐specific allergen‐
blocking antibodies as one of the main mechanisms of ASIT [21]. Blocking IgG, however, 
may also inhibit the presentation of antigen in APCs to antigen T cells and therefore suppress 
the activation of T cells induced [22]. ASIT can also alter the balance of specific helper T cells 
from a Th2 profile to an allergen‐specific Th1 immunity profile and can induce the secretion 
of immunoregulatory cytokines such as interleukin (IL)‐10, and regulatory T cells [23]. The 
induction of allergen‐specific tolerance is thus the essential immune mechanism of ASIT.
Recombinant hypoallergenic from variants have been produced. Linhart constructed, puri‐
fied, and characterized two hybrid hypoallergenic recombinant proteins from Brassica rapa 
allergens, Der p 2 (rder p 2)/1 C and rder p 2/1S [19]. Mutations in aspartic acid residues in 
these allergens decreased the cross‐linking of IgE in the membrane of sensitized mast cells by 
decreasing the allergenic potential of the protein [24].
Patients immunized in 2016 with a variant Bet v1 (birch allergen) hypoallergen did not 
develop a local allergic response, as observed by histopathological tests of skin contact. Rats 
immunized with the same recombinant hypoallergen demonstrated that a profile of tolero‐
genic responses with proinflammatory cytokine production was possible [25].
3.2.2. Synthetic peptides
Immunotherapy using peptides has some advantages over immunotherapies fusing recom‐
binant allergens. Vaccines using peptides with T cell epitopes can induce regulatory T cells. 
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The use of synthetic peptides derived from allergens containing T cell epitopes is an alterna‐
tive to the production of allergen‐specific T cells in ASIT. These peptides are formed from 
linear sequences representing fragments of small allergens that bind to the allergen‐specific 
T cell receptor and do not react with IgE antibodies, which give them an advantage because 
they do not trigger the classic allergic symptoms measured by IgE. The treatment may 
induce T cell tolerance by the secretion of the immune cytokine regulator IL‐10 from regu‐
latory T cells. The diversity of T cell epitopes is a possible disadvantage of vaccines based on 
T cell epitopes, making treatment with only one or a few peptides difficult. This treatment 
can cause secondary systemic symptoms and lacks the ability to induce IgG blocking [2].
Vaccines for allergies based on B cell epitopes of approximately 20–40 amino acids use pep‐
tides that lack the ability to bind IgE. The peptides must be covalently linked to a protein 
transporter that is unrelated to the T allergens in order to render these peptides immuno‐
genic, capable of inducing the production of IgG, which blocks the binding of IgE to the cor‐
responding allergen. Valenta et al. demonstrated the use of carrier‐linked allergenic peptides 
to induce IgG antibodies to the main pollen allergen of thyme grasses, Phl p 1, and to the main 
birch pollen allergen, Bet v 1. These conjugates decreased allergenic activity even more than 
the recombinant hypoallergens, because the non‐IgE‐reactive peptides were selected from the 
IgE‐binding sites [21].
3.3. Allergen‐nonspecific therapy
3.3.1. Anti‐IgE antibodies
The new approaches for the treatment of allergic diseases have two main strategies using 
nonspecific allergens [26]. The first strategy is to bind IgE to high‐affinity receptors (FcϵRI) in 
mast cells and basophils, and the second strategy is to interfere with the signaling generated 
by receptor binding (FcϵRI) [26, 27]. Knowledge of the pathophysiological role of IgE antibod‐
ies has allowed the development of new drugs against many allergic diseases.
3.3.2. Anti‐IgE receptor antibodies
A currently promising therapeutic approach has been the use of antibodies against the region 
of the IgE molecule that interacts with specific IgE receptors. The interaction of IgE molecules 
with high‐ and low‐affinity receptors may be inhibited by the use of anti‐IgE for reducing 
the induced allergic responses, preventing the activation of mast cells and consequently the 
release of allergic mediators [2, 26]. Omalizumab is a murine anti‐human IgE monoclonal 
antibody that binds to the same receptor site (Cε3) to which IgE binds, thereby inhibiting the 
binding of IgE‐to‐IgE receptors [2, 8]. Omalizumab does not bind to fixed IgE in cells, because 
the IgE epitope (specific fragment) against which omalizumab is targeted is already fixed to 
the receptors and is therefore hidden. Anti‐IgE therapy is most commonly used to treat bron‐
chial asthma but is also effective for treating allergic rhinoconjunctivitis, but therapy must 
begin before the pollen season [26]. The anti‐IgE therapy is currently being studied for use in 
food allergies, but the cost has limited its use for this purpose [1].
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3.3.3. IgE blocker
A new proposal has been studied by Deus‐de‐Oliveira et al. for blocking IgE‐allergen 
binding. The identification of the IgE‐binding epitopes and the amino acids involved in 
these interactions are fundamental steps. Deus‐de‐Oliveira et al. found that two glutamic 
acid residues in the main allergens of Ricinus communis, Ric c1 and Ric c 3, are involved 
in IgE binding, triggering an allergic response. They also found that the Ricinus allergens 
cross‐reacted with aeroallergens and food allergens from several sources. Free glutamic 
acid can bind to castor‐allergen‐specific IgE, occupying the epitope‐interaction site and 
preventing the binding of the allergens in a second exposure to the IgEs fixed in the mast 
cells. IgE blockade may be a safe approach for the treatment of allergy but will depend 
on determining the structures of allergens and on identifying epitopes and cross‐allergen 
responses.
A summary of strategies for treating allergies is presented in Table 3.
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Method Advantages Disadvantages
Antihistamines • Alleviate the symptoms triggered by the 
body’s responses to allergens
• Effective and safe
• May cause undesirable side effects on the 
central nervous system
• Side effects include sleepiness, sedation 
and fatigue that may lead to reduced 
cognitive, memory, and psychomotor 
performance
Allergen‐specific 
immunotherapy
• Reduces the sensitivity and conse‐
quently decreases symptomatic reactions
• Specific to particular allergens
Allergen‐nonspecific 
therapy (anti‐IgE 
antibodies)
• Reduces the induced allergic responses 
preventing the activation of mast cells 
and consequently the release of allergic 
mediators
• Does not bind to fixed IgE in cells because 
the IgE epitope (specific fragment) against 
which omalizumab is targeted is already 
fixed to the receptors and is therefore 
masked
IgE blocker • Blockade of IgE sites involved in the 
interaction with allergenic epitopes
• Under development
Table 3. Summary of strategies for treating allergies.
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